209 related articles for article (PubMed ID: 8626255)
1. Azole drug resistance in yeasts.
Johnson EM; Warnock DW
J Antimicrob Chemother; 1995 Nov; 36(5):751-5. PubMed ID: 8626255
[No Abstract] [Full Text] [Related]
2. [Antifungal agent resistance of yeasts of clinical significance].
Odds FC
Rev Clin Esp; 1995 Oct; 195 Suppl 3():56-7. PubMed ID: 9441307
[No Abstract] [Full Text] [Related]
3. Can we prevent azole resistance in fungi?
Denning DW
Lancet; 1995 Aug; 346(8973):454-5. PubMed ID: 7637473
[No Abstract] [Full Text] [Related]
4. Oral azole drugs as systemic antifungal therapy.
Como JA; Dismukes WE
N Engl J Med; 1994 Jan; 330(4):263-72. PubMed ID: 8272088
[TBL] [Abstract][Full Text] [Related]
5. Azole antifungal agents.
Bodey GP
Clin Infect Dis; 1992 Mar; 14 Suppl 1():S161-9. PubMed ID: 1314105
[TBL] [Abstract][Full Text] [Related]
6. Role of azoles in antifungal therapy.
Kauffman CA
Clin Infect Dis; 1996 May; 22 Suppl 2():S148-53. PubMed ID: 8722843
[TBL] [Abstract][Full Text] [Related]
7. Clinical predictors of azole resistance, outcome and survival from oesophageal candidiasis in AIDS patients.
Laing RB; Brettle RP; Leen CL
Int J STD AIDS; 1998 Jan; 9(1):16-20. PubMed ID: 9518009
[TBL] [Abstract][Full Text] [Related]
8. Use of azoles for systemic antifungal therapy.
Kauffman CA; Carver PL
Adv Pharmacol; 1997; 39():143-89. PubMed ID: 9160115
[No Abstract] [Full Text] [Related]
9. Candidiasis at ICAAC.
Barr D; Smart T
GMHC Treat Issues; 1995 Oct; 9(10):13. PubMed ID: 11362914
[TBL] [Abstract][Full Text] [Related]
10. [Clinical fluconazole and itraconazole resistance of oro-gastrointestinal candidiasis in a patient with AIDS].
Tebbe B; Boyvat A; Geilen CC; Wölfer LU; Seibold M; Orfanos CE
Hautarzt; 1996 Feb; 47(2):136-9. PubMed ID: 8868459
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of candidiasis and cryptococcosis in AIDS].
Just-Nübling G
Mycoses; 1994; 37 Suppl 2():56-63. PubMed ID: 7609745
[TBL] [Abstract][Full Text] [Related]
12. Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression.
Walmsley S; King S; McGeer A; Ye Y; Richardson S
Clin Infect Dis; 2001 Jun; 32(11):1554-61. PubMed ID: 11340526
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection.
Tumbarello M; Caldarola G; Tacconelli E; Morace G; Posteraro B; Cauda R; Ortona L
J Antimicrob Chemother; 1996 Oct; 38(4):691-9. PubMed ID: 8937963
[TBL] [Abstract][Full Text] [Related]
14. Azole resistance in Candida.
Denning DW; Baily GG; Hood SV
Eur J Clin Microbiol Infect Dis; 1997 Apr; 16(4):261-80. PubMed ID: 9177959
[TBL] [Abstract][Full Text] [Related]
15. Discovering antimycotic drugs: today and tomorrow.
Jacobs PH; Nall L
Cutis; 1990 Apr; 45(4):245-50. PubMed ID: 2158417
[No Abstract] [Full Text] [Related]
16. The role of azole antifungal agents for systemic antifungal therapy.
Lee YP; Goldman M
Cleve Clin J Med; 1997 Feb; 64(2):99-106. PubMed ID: 9046687
[TBL] [Abstract][Full Text] [Related]
17. Treatment of systemic mycoses in patients with AIDS.
Graybill JR
Arch Med Res; 1993; 24(4):403-12. PubMed ID: 8118165
[TBL] [Abstract][Full Text] [Related]
18. Azole antifungal drugs: old and new.
Dismukes WE
Ann Intern Med; 1988 Aug; 109(3):177-9. PubMed ID: 2839058
[No Abstract] [Full Text] [Related]
19. [Commonly used antifungal agents in the treatment of systemic mycoses].
Berenguer Berenguer J
Rev Clin Esp; 1995 Oct; 195 Suppl 3():58-65. PubMed ID: 9441308
[No Abstract] [Full Text] [Related]
20. [Candida infection of the skin and mucous membranes still a topic. Administering azoles with clinical understanding].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():80. PubMed ID: 12043087
[No Abstract] [Full Text] [Related]
[Next] [New Search]
